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Treatment of Latent Tuberculosis Infection and Tuberculosis Disease 
BACKGROUND 
In this module, you will learn about the principles of treating latent TB infection (LTBI) and TB 
disease. A person with LTBI is treated to prevent them from progressing to TB disease. Some 
people with LTBI are at very high risk of developing TB disease, and they should receive high 
priority for LTBI treatment. TB disease is treated to cure the patient and to stop the spread of 
TB. As a health care worker, you may be responsible for helping TB patients take their 
medications as prescribed. This is very important because patients with TB disease who do not 
complete treatment as prescribed may become infectious or develop drug-resistant TB; patients 
with LTBI who do not complete treatment as prescribed can unnecessarily develop TB disease. 
This module also explains the possible side effects of the drugs used to treat LTBI and TB 
disease. If you have regular contact with TB patients, you should be aware of the signs and 
symptoms of these side effects. If a patient has symptoms of a serious side effect, you should 
notify a clinician immediately. 
OBJECTIVES 
After working through this module, you will be able to 
1. List the groups of people who should receive high priority for LTBI treatment. 
2. Describe treatment regimens for LTBI. 
3. Describe treatment regimens for TB disease. 
4. Describe the principles of preventing drug resistance. 
5. Describe patient monitoring during LTBI and TB disease treatment. 
6. Describe TB treatment adherence strategies. 
7. List the common adverse reactions to the drugs used to treat LTBI and TB disease. 
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Treatment of Latent Tuberculosis Infection and Tuberculosis Disease 
NEW TERMS 
Look for the following new terms in this module and in the glossary.  
adherence to treatment – following the 
recommended course of treatment by taking all 
the prescribed medications for the entire length 
of time necessary 
adverse reaction – negative side effect 
resulting from the use of a drug (for example, 
hepatitis, nausea, headache) 
antiretroviral therapy (ARV) – a lifelong 
combination drug treatment to improve the 
quality and length of life for a person living 
with HIV/AIDS 
case management – a system in which a 
specific health department employee is 
assigned primary responsibility for the patient, 
systematic regular review of patient progress is 
conducted, and plans are made to address any 
barriers to adherence
clinical evaluation – an evaluation done to 
find out whether a patient has symptoms of TB 
disease or is responding to treatment; also done 
to check for adverse reaction to TB 
medications 
continuation phase – the period after the first 
8 weeks of TB disease treatment, during which 
tubercle bacilli that remain after the initial 
phase are treated with at least two drugs 
daily regimen – a treatment schedule in which 
the patient takes a dose of each prescribed 
medication every day 
directly observed therapy (DOT) – a strategy 
devised to help patients adhere to treatment; a 
designated person watches the TB patient 
swallow each dose of the prescribed drugs 
ethambutol (EMB) – a drug used to treat TB 
disease; may cause vision problems. 
Ethambutol should be used cautiously in 
children who are too young to be monitored for 
changes in their vision 
extensively drug resistant TB (XDR TB) – a 
rare type of MDR TB which is resistant to 
isoniazid and rifampin, plus resistant to any 
fluoroquinolone and at least one of three 
injectable second-line drugs (i.e., amikacin, 
kanamycin, or capreomycin)
hepatitis – inflammation of the liver, causing 
symptoms such as nausea, vomiting, 
abdominal pain, fatigue, and dark urine; 
hepatitis can be caused by several drugs used 
to treat LTBI or TB disease
initial phase – the first 8 weeks of TB disease 
treatment, during which most of the tubercle 
bacilli are killed 
intermittent therapy – a treatment schedule in 
which the patient takes each prescribed 
medication two or three times weekly at the 
appropriate dosage 
isoniazid (INH) – a drug that is used for 
treating LTBI and TB disease; although 
relatively safe, it may cause hepatitis and other 
adverse reaction in some patients 
liver function tests – tests done to detect 
injury to the liver
LTBI treatment – medication that is given to 
people who have TB infection to prevent them
from developing TB disease 
multidrug-resistant TB (MDR TB) – TB that 
is resistant to isoniazid and rifampin; more 
difficult to treat than drug-susceptible TB 
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Treatment of Latent Tuberculosis Infection and Tuberculosis Disease 
peripheral neuropathy – damage to the 
sensory nerves of the hands and feet, causing a 
tingling sensation or a weakened sense of 
touch in the hands and feet
primary TB – primary TB generally affects 
the mid and lower lung; in children this form
of TB is much more common
pyridoxine – another name for vitamin B6; it 
is given to prevent peripheral neuropathy; 
should always be given to pregnant and 
breastfeeding women on isoniazid 
reactivation (post-primary) TB – TB that 
generally affects upper lobes; sometimes with 
cavities and is usually found in adults. 
Sometimes called adult-type TB
rifabutin – a drug used to treat TB disease; 
used as a substitute for rifampin (RIF) in the 
treatment of all forms of TB
rifampin (RIF) – a drug used to treat TB 
disease; also used for LTBI treatment. 
Rifampin has several possible side effects (for 
example, hepatitis, turning body fluids orange, 
drug interactions) 
rifapentine – a drug used to treat TB disease; 
used once weekly with isoniazid during the 
continuation phase with selected HIV negative 
patients 
XDR TB – see extensively drug resistant TB 
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READING MATERIAL 
Treatment of Latent TB Infection (LTBI) 

. . . . . . . . . . . . . . . . . . . . . . . . 
LTBI is treated to prevent 
people who have TB 
infection from developing 
TB disease.
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
People in certain groups 
should receive high priority 
for LTBI treatment if they 
have a positive TST or 
QFT-G result. 
. . . . . . . . . . . . . . . . . . . . . . . . 
Why is LTBI treated? 
LTBI is treated to prevent people who have TB infection 
from developing TB disease. LTBI is treated with 
medication.  
Who should receive LTBI treatment? 
Some groups of people are at higher risk for TB than others 
(see Module 2, Epidemiology of TB). These groups can be 
divided into two categories 
 People who are at higher risk for becoming infected 
with M. tuberculosis
 People who are higher risk for developing TB disease 
once infected with M. tuberculosis
People in these groups should be identified through 
targeted testing programs. Once identified, people in these 
groups should receive high priority for treatment of LTBI if 
they have a positive tuberculin skin test (TST) or a 
QuantiFERON-TB Gold® (QFT-G) test (see Module 3, 
Targeted Testing and the Diagnosis of Latent Tuberculosis 
Infection and Tuberculosis Disease).
The criteria for determining who should receive high 
priority for LTBI treatment are listed in the following table 
(Table 4.1). 
4
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
      
  
     
 
 
Treatment of Latent Tuberculosis Infection and Tuberculosis Disease 
Table 4.1 

High-Priority Candidates for LTBI Treatment Using a TST or QFT-G* 

People in these groups should be given People in these groups should be given 
high priority for LTBI treatment if they high priority for treatment of LTBI if 
have a positive QFT-G result or a TST they have a positive QFT-G result or a 
reaction* that is 5 or more millimeters TST reaction that is 10 or more 
millimeters
 Recent close contacts of people with  People who have come to the U.S. 
infectious TB disease** within the last 5 years from areas of the 
 People living with HIV** world where TB is common (for 
 People with chest x-ray findings 
suggestive of previous TB disease 
 Patients with organ transplants 
 Other immunosuppressed patients 
(such as patients on prolonged 
therapy with corticosteroids, 
equivalent to taking 15 mg or more of 
prednisone, or those taking TNF-
example, Asia, Africa, Eastern Europe, 
Russia, or Latin America) 
 People who inject illegal drugs 
 People who live or work in high-risk 
facilities (for example, nursing homes, 
correctional facilities, homeless shelters, 
hospitals, or other health care facilities) 
 People who work in mycobacteriology 
alpha antagonists)** laboratories 
 People with medical conditions that 
appear to increase the risk for TB 
disease (silicosis, diabetes mellitus, 
severe kidney disease, certain types of 
cancer, and certain intestinal conditions) 
 Children younger than 4 years old 
 Infants, children, and adolescents 
exposed to adults in high-risk groups**
 *See Module 3, Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis
Disease, for information on interpreting a TST or QFT-G result. 
**In certain circumstances, people in these categories may be given LTBI treatment even if they do not
have a positive TST or QFT-G result (see the Special Considerations for LTBI Treatment section in this 
Module).
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. . . . . . . . . . . . . . . . . . . . . . . . 
It is necessary to make sure 
that the person does not have 
active TB disease before 
starting LTBI treatment. 
. . . . . . . . . . . . . . . . . . . . . . . . 
People without any risk factors should generally not be 
tested for TB infection. Testing should be targeted to 
groups at high risk for LTBI and TB disease (see Module 3, 
Targeted Testing and the Diagnosis of Latent Tuberculosis 
Infection and Tuberculosis Disease). However, if a person 
without any risk factors is tested and has a positive QFT-G 
result or TST reaction that is 15 mm or more, they should 
be evaluated for LTBI treatment. It is necessary to make 
sure that the person does not have active TB disease before 
starting LTBI treatment. 
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Treatment of Latent Tuberculosis Infection and Tuberculosis Disease 
Study Questions 4.1 – 4.3 
4.1	 What is the purpose of LTBI treatment?
4.2	 Which groups of people should receive high priority for LTBI treatment if they 
have a positive QFT-G result or a TST reaction with an induration that is 5
millimeters or larger? Name five. 
4.3	 Which groups of people should receive high priority for LTBI treatment if they 
have a positive QFT-G result or a TST reaction with an induration that is 10
millimeters or larger? Name seven.  
Answers to study questions are on pages 52 – 58. 
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eatment of Latent Tuberculosis Infection and Tuberculosis Disease 
. . . . . . . . . . . . . . . . . . . . . . . . 
The preferred regimen for 
LTBI treatment is isoniazid 
given daily for 9 months. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
People with HIV, children, 
and people with previous TB 
disease should receive 9 
months of isoniazid for LTBI 
treatment.  
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
Rifampin can be used to treat 
individuals who cannot 
tolerate isoniazid or who 
have been exposed to 
isoniazid-resistant TB.  
. . . . . . . . . . . . . . . . . . . . . . . . 
Regimens for LTBI Treatment 
There are several treatment regimens available for LTBI 
(Table 4.2). The drug isoniazid (also known as INH), is 
usually used alone to treat LTBI. For more detailed 
information on treating LTBI, please refer to the CDC 
Targeted Tuberculin Testing and Treatment of Latent TB 
Infection guidelines. 
Isoniazid – 9 Month Regimen
The preferred regimen for LTBI treatment is isoniazid 
given daily for 9 months. Nine months of isoniazid for 
LTBI treatment is very effective in preventing the 
development of TB disease in both people infected with 
HIV and those not infected with HIV. 
Isoniazid – 6 Month Regimen 
Six months of isoniazid can also provide protection, and 
may be preferred by some clinicians from a cost-
effectiveness standpoint and because some patients may 
find it easier to adhere to a shorter treatment regimen. 
However, since isoniazid for LTBI treatment is not always 
effective when it is given for less than 6 months, every 
effort must be made to ensure that patients receive it for at
least 6 months. Moreover, the 6-month treatment regimen 
is not recommended for people living with HIV, children, 
and people with chest x-ray findings suggestive of previous 
TB disease. These people should always receive isoniazid 
for 9 months. 
Alternative Regimens for LTBI Treatment 
Rifampin
In some situations, drugs other than isoniazid may be used 
for LTBI treatment. For example, the drug rifampin (RIF)
is recommended for people with a positive TST or QFT-G 
result who cannot tolerate isoniazid or have been exposed 
to isoniazid-resistant TB. LTBI treatment with rifampin 
should be given daily for 4 months to both adults and 
children. Rifampin should not be used in HIV-infected 
persons being treated with some combinations of 
antiretroviral (ARV) therapy. In situations where rifampin 
cannot be used, another drug, rifabutin, may be 
substituted. 
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Treatment of Latent Tuberculosis Infection and Tuberculosis Disease 
. . . . . . . . . . . . . . . . . . . . . . . 
The combination of rifampin 
and pyrazinamide should 
NOT be used for either 
people with or without HIV 
infection. 
. . . . . . . . . . . . . . . . . . . . . . . 
Rifampin and Pyrazinamide
Due to the reports of severe liver injury and death, CDC 
advises NOT using the combination of rifampin and 
pyrazinamide (PZA) for 2 months for LTBI treatment for 
either people with or without HIV infection. 
Table 4.2 
LTBI Treatment Regimens* 
Drug/Dose Duration (months) Interval 
Minimum 
Doses Comments 
Isoniazid 9 
Daily 270 
The preferred regimen is daily 
treatment for 9 months  
Recommended regimen for people 
with HIV, children, and people 
with chest x-ray findings 
suggestive of previous TB disease 
DOT should be used with twice-
weekly dosing
Twice 
weekly 76 
Isoniazid 6 
Daily 180 
Not recommended for people with 
HIV, children, and people with 
chest x-ray findings suggestive of 
previous TB disease 
DOT should be used with twice-
weekly dosing 
Twice 
weekly 52 
Rifampin 4 Daily 120 
Recommended for patients who 
have isoniazid-resistant, rifampin­
susceptible LTBI 
Alternative for people who cannot 
tolerate isoniazid 
Not recommended for HIV-
infected patients on certain 
combinations of ARV therapy; 
rifabutin may be used instead 
Rifampin/ 
Pyrazinamide Generally should not be offered for treatment of LTBI 
* For more detailed information on LTBI treatment, please refer to Targeted Tuberculin Testing and Treatment
of Latent TB Infection — MMWR 2000; 49 (No. RR–6). See “Additional Reading” for more information. 
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Treatment of Latent Tuberculosis Infection and Tuberculosis Disease 
Study Questions 4.4 – 4.5 
4.4	 What is the preferred LTBI treatment regimen?
4.5	 What LTBI treatment regimen may be recommended for people with a positive 
TST or QFT-G result who have been exposed to isoniazid-resistant TB?
Answers to study questions are on pages 52 – 58. 
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Treatment of Latent Tuberculosis Infection and Tuberculosis Disease 
. . . . . . . . . . . . . . . . . . . . . . . . 
DOT is a strategy used to 
help patients adhere to 
treatment. 
. . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
Some close contacts may start 
taking LTBI treatment if they 
have a negative TST or 
QFT-G result but less than 8 
to 10 weeks have passed 
since they were last exposed 
to TB. 
. . . . . . . . . . . . . . . . . . . . . . . . 
Special Considerations for LTBI Treatment 
Directly Observed Therapy (DOT) 
For people who are especially at high risk for TB, or who 
are suspected to be more likely to be non-adherent, directly 
observed therapy (DOT) for LTBI should be considered. 
DOT is a strategy used to help patients adhere to treatment. 
It means that a health care worker or another designated 
person watches the patient swallow each dose of the 
prescribed drugs. Patients on regimens given once or twice 
weekly may be more likely to miss doses, thus DOT is 
recommended for patients on intermittent therapy. For 
more information on DOT, see the Adherence to Treatment 
section of this module, page 39. 
Close Contacts 
Close contacts include people who have had recent or 
prolonged exposure to a person with known or suspected 
infectious TB. These people should be evaluated 
immediately for TB disease and LTBI. If their TST or 
QFT-G result is positive, they should be given high priority 
for LTBI treatment. If their TST or QFT-G is negative, the 
contacts should be retested in 8 to 10 weeks. This is due to 
the fact that it can take 2 to 8 weeks after TB infection for 
the body’s immune system to be able to react to tuberculin 
and for the infection to be detected by the TST. 
Sometimes LTBI treatment is given to people who have a 
negative TST or QFT-G result. For example, some close 
contacts at high risk for developing TB disease may start 
taking LTBI treatment if they have a negative skin test but 
less than 8 to 10 weeks have passed since they were last 
exposed to TB. These contacts include
	 Children who are 5 years old or younger (some TB 
programs may have different age cutoff guidelines) 
	 People living with HIV 
	 Other immunocompromised persons who may 

develop TB disease quickly after infection 

These contacts may be infected with M. tuberculosis but 
have a false-negative TST reaction because less than 8 to 
10 weeks have passed since they were last exposed to TB. 
(see Module 3, Targeted Testing and the Diagnosis of 
Latent Tuberculosis Infection and Tuberculosis Disease). 
11 

  
 
T
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
reatment of Latent Tuberculosis Infection and Tuberculosis Disease 
. . . . . . . . . . . . . . . . . . . . . . . . 
TB contacts living with HIV 
or others with a weakened 
immune system may be given 
a full course of LTBI 
treatment regardless of their 
second TST or QFT-G result. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
If a person is a contact of a 
patient with multidrug­
resistant (MDR) TB, the risk 
for developing TB disease 
should be considered before 
recommending LTBI 
treatment. 
. . . . . . . . . . . . . . . . . . . . . . . . 
Once active TB disease is ruled out, these contacts should 
start LTBI treatment to prevent them from rapidly 
developing TB disease. They also should be retested 8 to 
10 weeks after they were last exposed to TB. If they have a 
negative TST or QFT-G, they can stop taking the LTBI 
treatment. If they have a positive TST or QFT-G result, 
they should continue to take LTBI treatment. Contacts 
living with HIV or others with a weakened immune system
may be given a full course of LTBI treatment regardless of 
their second TST or QFT-G result. 
In general, contacts with a positive TST or QFT-G and a 
documented history of completion of LTBI treatment do 
not need to be retreated. However, re-treatment may be 
necessary for persons who are at high risk of becoming re-
infected and progressing to TB disease (for example, 
immunocompromised persons). 
Contacts of Isoniazid-Resistant TB 
If a person is a contact of a patient with isoniazid-resistant 
but rifampin-susceptible TB, a 4-month regimen of daily 
rifampin may be recommended. In situations where 
rifampin cannot be used, rifabutin may be substituted.
Contacts of Multidrug-Resistant TB
If a person is a contact of a patient with multidrug­
resistant (MDR) TB, the risk for developing TB disease 
should be considered before recommending LTBI 
treatment. MDR TB contacts may be treated for 6-12 
months or they can be observed for signs and symptoms of 
disease without treatment. 
If treating an MDR TB contact for LTBI, an alternative 
regimen of drugs to which the infecting organism is known 
to be susceptible should be used. Immunocompromised 
contacts (such as, persons who are HIV-infected) should be 
treated for 12 months. All persons with suspected MDR 
LTBI should be followed and observed for signs and 
symptoms of TB disease for 2 years, regardless of the 
treatment regimen. An expert in the treatment of MDR TB 
should also be consulted. 
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Treatment of Latent Tuberculosis Infection and Tuberculosis Disease 
. . . . . . . . . . . . . . . . . . . . . . . . 
Children who are 5 years old 
and younger and who have 
been exposed to TB should 
start taking LTBI treatment, 
even if they have a negative 
TST result.
. . . . . . . . . . . . . . . . . . . . . . . . 
Infants and Children 
Because of their age, infants and young children with a 
positive TST reaction are known to have been infected 
recently and are at high risk of rapidly developing TB 
disease. Infants and young children are also more likely 
than older children and adults to develop life-threatening 
forms of TB disease.  
Children who are 5 years old and younger who have been 
exposed to TB should start taking LTBI treatment, even if 
they have a negative TST result. This is because they are at 
high risk of rapidly developing TB disease and because 
they may have a false-negative TST reaction (see Module 
3, Targeted Testing and the Diagnosis of Latent 
Tuberculosis Infection and Tuberculosis Disease). 
Children should be retested 8 to 10 weeks after they were 
last exposed to TB. 
LTBI treatment can be stopped if ALL of the following 
conditions are met: 
	 The second TST is negative. 
	 The second TST was done 8 to 10 weeks after the 

child was last exposed to TB. 

	 The child is at least 6 months old. 
Currently, there are limited data on diagnosing TB
infection using QFT-G in children younger than 17. 
13 
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. . . . . . . . . . . . . . . . . . . . . . . . 
Pregnant women should not 
be given LTBI treatment until 
after delivery, unless they 
have certain medical 
conditions. 
. . . . . . . . . . . . . . . . . . . . . . . . 
Pregnant Women 
For most pregnant women with TB infection, LTBI 
treatment can be delayed until after delivery, even though 
isoniazid has NOT been shown to have harmful effects on 
the fetus. If the woman does not have any high risk factors 
for developing TB disease, treatment should be given after 
she has delivered her baby, so she can avoid having to take 
unnecessary medications during pregnancy. If the pregnant 
woman is HIV-infected or a recent contact, immediate 
treatment should be considered. The preferred LTBI 
treatment regimen for pregnant women is 9 months of 
isoniazid with a vitamin B6 supplement (also know as 
pyridoxine).
Breastfeeding Women 
Women who are breastfeeding can take isoniazid, but they 
should also be given a vitamin B6 supplement. The amount 
of isoniazid found in the breast milk, however, is not 
enough to be considered as treatment for the infant.  
People with HIV Infection 
People with HIV infection should be treated with a 9­
month regimen of isoniazid. Rifampin should not be used 
for an HIV-infected person who is being treated with a 
certain combination of antiretroviral therapy (ARV). In 
these cases, rifabutin may be given instead. 
14
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Treatment of Latent Tuberculosis Infection and Tuberculosis Disease 
Study Questions 4.6 – 4.8 
4.6	 In what circumstances may LTBI treatment be given to people who have a 
negative TST or QFT-G result?
4.7	 What conditions must be met to stop LTBI treatment for children, 5 years and 
younger, who were exposed to TB?
4.8	 When should pregnant women be treated for LTBI and for how long?
Answers to study questions are on pages 52 – 58. 
15 
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Case Study 4.1 
You are sent to visit the home of a TB patient who was admitted to the hospital 
last week and diagnosed with infectious TB disease. Living in the home are his 
wife and his 1-year-old daughter. Neither one has symptoms of TB disease. You 
give them both a tuberculin skin test and return 2 days later to read the results. 
You find that the wife has 14 mm of induration, but the daughter has no 
induration. 
 Should either one be evaluated for LTBI treatment? 
 Why or why not? 
Answers to case study questions are on pages 59 – 62. 
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Treatment of Latent Tuberculosis Infection and Tuberculosis Disease 
. . . . . . . . . . . . . . . . . . . 
All persons being 
considered for LTBI 
treatment should 
receive a medical 
evaluation. 
. . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . 
The possibility of 
TB disease should 
be excluded before 
starting LTBI 
treatment. 
. . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . 
It is also important
to determine 
whether the patient
has ever been 
treated for TB
infection or disease.  
. . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . 
It is important to 
find out if the 
patient is on other 
medications or has 
any medical 
problems that may 
complicate therapy. 
. . . . . . . . . . . . . . . . . . . 
Patient Medical Evaluation and Monitoring for LTBI 
Treatment 
Patient Medical Evaluation 
All persons being considered for LTBI treatment should receive a 
medical evaluation. One reason for this evaluation is to exclude the 
possibility of TB disease. Treating TB disease with a LTBI 
treatment regimen (usually a single drug) can lead to drug resistance 
(see the Preventing Drug Resistance section in this Module, page 
24). To rule out the possibility of TB disease, clinicians should 
determine whether the patient has symptoms of TB disease, and they 
should evaluate the patient with a chest x-ray. People with 
symptoms of TB disease or chest x-ray findings suggestive of TB 
disease should be given treatment for TB disease, not LTBI.
It is also important to determine whether the patient has ever been 
treated for TB infection or disease. In general, people who have been 
adequately treated should not be treated again. The TST or QFT-G 
cannot be used to determine whether a patient has received treatment 
for TB infection or disease. This is because most people who have a 
positive TST reaction will have another positive reaction if they are 
skin tested later in their lives, regardless of whether they have 
received treatment. Furthermore, there is currently not enough data 
on the ability of the QFT- G to detect re-infection after treatment for 
both LTBI and TB disease. Thus, some people may require re-
treatment if they are at risk of becoming re-infected and progressing 
to TB disease (for example, immunocompromised people). Persons 
who complete LTBI treatment should be given documentation. 
Another reason for the medical evaluation is to find out whether the 
patient has other medical problems that may complicate therapy or 
require more careful monitoring. These patients include  
	 People living with HIV 
	 People with a history of liver disorder or disease 
	 People who use alcohol regularly 
	 Women who are pregnant or just had a baby (within 3 months 
of delivery) 
	 People who are taking other medications that may increase the 
risk of hepatitis 
For these patients, baseline laboratory liver function tests are 
recommended before starting LTBI treatment. 
17 
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. . . . . . . . . . . . . . . . . . . 
Medical evaluation 
allows health care 
providers to build 
and establish rapport 
with patients. 
. . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . 
Health care workers 
should recommend 
that patients undergo 
HIV testing and 
counseling. 
. . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . 
A major risk of 
isoniazid is hepatitis 
(inflammation of the 
liver).
. . . . . . . . . . . . . . . . . . . . 
It is also important to find out if the patient has ever had any 
adverse reactions to drugs used for LTBI treatment or if they are 
currently on medications that may interact with LTBI treatment 
drugs. 
Finally, conducting a medical evaluation provides the health care 
worker an opportunity to build and establish rapport with the 
patient. Health care workers should highlight the important aspects 
of treatment, such as: 
 Benefits of treatment 
 Importance of adherence to treatment 
 Possible adverse reactions 
 Establishment of a follow-up plan 
Because of the interaction between TB and HIV, health care 
workers should also recommend that patients undergo HIV 
counseling and testing. 
Adverse Reactions to Isoniazid 
Many health care providers have concerns about treating patients 
for LTBI. These concerns are generally related to the length of the 
treatment and the fact that sometimes medications cause adverse 
reactions, or negative side effects. As many as 10%-20% of people 
treated with isoniazid will have some mild, abnormal liver function 
tests results (tests done to detect damage to the liver) during 
treatment. In most people, these test results return to normal even 
when isoniazid treatment is continued. As with any treatment, the 
risks and benefits of LTBI treatment must be weighed for each 
individual. For example, isoniazid may cause hepatitis, or 
inflammation of the liver. Hepatitis prevents the liver from
functioning normally, causing symptoms such as 
 Nausea 
 Vomiting 
 Abdominal pain 
 Fatigue 
 Dark urine 
Isoniazid can cause hepatitis in anyone; however, hepatitis occurs 
in less than 1% of people taking isoniazid. Many things can cause 
hepatitis, including various viruses and other medications. 
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Treatment of Latent Tuberculosis Infection and Tuberculosis Disease 
. . . . . . . . . . . . . . . . . . . . 
Some factors, such as 
older age and 
alcoholism, increase 
the risk that isoniazid 
will cause serious 
hepatitis. 
. . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . 
Isoniazid can damage 
the sensory nerves of 
the hands and feet. 
. . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . 
All persons taking 
LTBI treatment should 
be educated about the 
symptoms caused by 
adverse reactions to 
isoniazid. 
. . . . . . . . . . . . . . . . . . . . 
There are certain risk factors that increase the risk of serious 
hepatitis. Alcoholism is one risk factor. Age is another factor; 
older persons are at higher risk for hepatitis. Although rare, there 
have been some cases of severe and fatal hepatitis in patients 
younger than 20 years old. 
Isoniazid can also damage the sensory nerves of the hands and 
feet. This is called peripheral neuropathy. The main symptom 
of peripheral neuropathy is a tingling sensation or a weakened 
sense of touch in the hands and feet. Some conditions, such as 
alcoholism, diabetes, and malnutrition, increase the risk for 
peripheral neuropathy. People with these conditions should be 
given vitamin B6, also known as pyridoxine. Vitamin B6 should 
also be given to pregnant or breastfeeding women who are taking 
isoniazid. 
Patients taking rifampin should also be aware of possible adverse 
effects. Hepatitis is more likely to occur when rifampin is 
combined with isoniazid. Some other side effects from rifampin
include: 
	 Rash 
	 Gastrointestinal symptoms (nausea, anorexia, and 

abdominal pain) 

	 Orange discoloration of urine, saliva, and tears; soft contact 
lenses may be permanently stained  
	 Increased sensitivity to the sun 
	 Interaction with other drugs, such as birth control pills and 
implants, warfarin, and methodone 
Patient Monitoring  
All patients taking LTBI treatment should be educated about the 
symptoms that are caused by adverse reactions to isoniazid and 
rifampin. These patients should be instructed to stop taking the 
medication and seek medical attention immediately if serious 
symptoms occur (Table 4.5).
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Treatment of Latent Tuberculosis Infection and Tuberculosis Disease 
. . . . . . . . . . . . . . . . . . . 
All persons receiving 
LTBI treatment should 
be evaluated at least 
monthly during therapy 
for signs and symptoms 
of active TB disease 
and adverse reactions. 
. . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . 
People at greatest risk 
for hepatitis should 
have liver function 
tests before starting 
isoniazid LTBI 
treatment and every 
month during therapy. 
. . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . 
All patients should 
receive documentation 
upon completion of 
LTBI treatment. 
. . . . . . . . . . . . . . . . . . . . 
All persons receiving LTBI treatment should also be evaluated at 
least monthly during therapy for
	 Adherence to the prescribed regimen  
	 Signs and symptoms of active TB disease  
	 Adverse reactions (such as signs and symptoms of hepatitis) 
During each monthly evaluation, patients should be asked 
whether they have nausea, abdominal pain, or any of the other 
symptoms that may be caused by adverse reactions. In addition, 
health care workers should examine patients for signs of these 
adverse reactions. Patients should be instructed to stop taking 
medications and contact their health care providers immediately 
if they have any signs or symptoms of hepatitis (Table 4.5). 
People at greatest risk for hepatitis should have baseline liver 
function tests before starting LTBI treatment and during therapy. 
This includes 
	 People living with HIV 
	 People with a history of liver disorder or disease 
	 People who use alcohol regularly 
	 Women who are pregnant or just had a baby (within 3 

months of delivery) 

	 People who are taking other medications that may increase 
the risk of hepatitis 
For all patients, isoniazid should be stopped if the results of liver 
function tests are three times higher than the upper limit of the 
normal range and the patient has symptoms, or if the results are 
five times higher than the upper limit of the normal range and the 
patient is asymptomatic.
Treatment Follow-up 
Patients should receive documentation of TST or QFT-G results, 
regimens, and treatment completion dates. The patient should be 
told to present this document any time they are required to be 
tested for TB. Patients should also be re-educated about the signs 
and symptoms of TB disease. For detailed information on the 
treatment of LTBI, please refer to the CDC Targeted Tuberculin 
Testing and Treatment of Latent TB Infection guidelines. 
20

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
    
 
 
 
 
 
e Treatment of Latent Tuberculosis Infection and Tuberculosis Diseas
Study Questions 4.9 – 4.13 
4.9 Name four reasons why patients should receive a medical evaluation before 
starting LTBI treatment. 
4.10 Why is it important to exclude the possibility of TB disease before giving a 
patient LTBI treatment? 
4.11 What are the symptoms of hepatitis? 
4.12 Who is at greatest risk for hepatitis? What special precautions should be taken 
for these patients?  
4.13 How often should patients be evaluated for signs and symptoms of adverse 
reactions during LTBI treatment?
Answers to study questions are on pages 52 – 58. 
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Treatment of Latent Tuberculosis Infection and Tuberculosis Disease 
Case Study 4.2 
A 65-year-old man is prescribed isoniazid LTBI treatment because he is a close 
contact of a person with infectious TB and he has an induration of 20 mm to the 
tuberculin skin test. His baseline liver function tests are normal, but he drinks a 
six-pack of beer every day. 
 What kind of monitoring is necessary for this patient while he is taking
isoniazid? 
Answers to case study questions are on pages 59 – 62. 
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Treatment of Latent Tuberculosis Infection and Tuberculosis Disease 
Treatment of TB Disease 

. . . . . . . . . . . . . . . . . . . . . . . . 
TB disease must be treated 
for at least 6 months; in some 
cases, treatment lasts even 
longer. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
Initial regimen for treating 
TB disease should include 
four drugs: isoniazid, 
rifampin, pyrazinamide,  
and ethambutol. 
. . . . . . . . . . . . . . . . . . . . . . . . 
Treating TB disease benefits both the person who has TB 
and the community. It helps the patient because it prevents 
disability and death and restores health; it benefits the 
community because it prevents the further transmission of 
TB. 
TB disease must be treated for at least 6 months; in some 
cases, treatment lasts even longer. Most of the tubercle 
bacilli are killed during the first 8 weeks of treatment (the 
initial phase). However, a few bacilli can survive. 
Therefore, treatment with at least two drugs must be 
continued for several more months to kill these remaining 
bacilli (the continuation phase). If treatment is not 
continued for a long enough time, the surviving bacilli may 
cause TB disease in the patient at a later time (relapse). 
TB treatment regimens must contain multiple drugs to 
which the organisms are susceptible. Treatment with a 
single drug can lead to the development of drug-resistant 
TB. The initial regimen for treating TB disease should 
include the following four drugs (Figure 4.1):   
 Isoniazid (INH) 
 Rifampin (RIF) 
 Pyrazinamide (PZA) 
 Ethambutol (EMB)  
When the drug susceptibility results are available, 
clinicians may change the regimen accordingly. For 
detailed information on the treatment of TB, please refer to 
the ATS, CDC, and IDSA Treatment of Tuberculosis
guidelines. 
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Treatment of Latent Tuberculosis Infection and Tuberculosis Disease 
. . . . . . . . . . . . . . . . . . . . . . . . 
TB disease must be treated 
with at least two drugs to
which the bacilli are 
susceptible.
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
Drug resistance can develop 
when patients are prescribed 
an inappropriate regimen for 
treatment or when patients do 
not follow treatment 
regimens as prescribed. 
. . . . . . . . . . . . . . . . . . . . . . . . 
Preventing Drug Resistance 
Drug resistance can develop when patients are prescribed 
an inappropriate regimen for treatment. TB disease must be 
treated with at least two drugs to which the bacilli are 
susceptible. Using only one drug to treat TB disease can 
create a population of tubercle bacilli resistant to that drug. 
When two or more drugs are used together, each drug helps 
prevent the emergence of bacilli that are resistant to the 
other drugs. When a patient is not improving in response to 
a prescribed regimen, adding a single drug to that regimen 
may have the same effect as using only one drug for 
treatment: it can lead to drug resistance.  
Drug resistance can also develop when patients do not 
follow treatment regimens as prescribed — in other words, 
if they do not take all of their pills, if they do not take their 
pills as often as prescribed, or both. When this happens, the 
patients may expose the bacilli to a single drug. 
Drug resistance is more common in people who have spent 
time with someone with active drug resistant TB disease. 
Following are factors that increase the chance of a patient 
having or developing drug-resistant TB.  
	 Patient does not take their medicine regularly 
	 Patient does not take all of their medicine, as told by 
their health care provider 
	 Patient develops active TB disease again, after having 
taken TB medicine in the past 
	 Patient comes from areas of the world where drug-
resistant TB is common 
For more information on the development of drug-resistant 
TB, see Module 1, Transmission and Pathogenesis of 
Tuberculosis. 
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Treatment of Latent Tuberculosis Infection and Tuberculosis Disease 
Treatment Regimens 
There are several options for daily and intermittent therapy. 
The recommended regimens are described in Table 4.3; the 
recommended dosages for the most common drugs are 
listed in Table 4.4. These tables are provided for you to use 
as a reference. For detailed information on TB Treatment, 
please refer to the ATS, CDC, and IDSA Treatment of 
Tuberculosis guidelines. 
    Figure 4.1 Drugs used to treat TB disease. From left to right:  isoniazid, rifampin,
 pyrazinamide, and ethambutol. 
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Treatment of Latent Tuberculosis Infection and Tuberculosis Disease 
Table 4.3 

Drug Regimens for Pulmonary TB Caused by Drug Susceptible Organisms in Adults* 

Initial Phase Continuation Phase 
Regimen Drugs Interval and Doses± Regimen Drugs Interval and Doses± § Range of Total Doses 
1 INH 
RIF 
PZA
EMB
7 days/week for 56 doses (8 
weeks) 
or
5 days /week for 40 doses 
(8 weeks)¶ 
1a INH 
RIF 
7 days/week for 126
doses (18 weeks) 
or 
5 days/week for 90 doses 
(18 weeks) ¶ 
182-130 
(26 weeks) 
1b# INH 
RIF 
2 days/week for 36 doses 
(18 weeks) ¶ 
92-76 
(26 weeks) 
1c** INH 
RPT 
1 day/week for 18 doses 
(18 weeks) ¶ 
74-58 
(26 weeks) 
2 INH 
RIF 
7 days/week for 14 doses (2 
weeks), then 2 days/week 
2a# INH 
RIF 
2 days/week for 36 doses 
(18 weeks) ¶ 
62-58 
(26 weeks) 
PZA
EMB
for 12 doses (6 weeks) 
or 
5 days/week for 10 doses 
(2 weeks), ¶ then 2 
days/week for 12 doses (6 
weeks) 
2b** INH 
RPT 
1 day/week for 18 doses 
(18 weeks) ¶ 
44-40 
(26 weeks) 
3 INH 
RIF 
PZA
EMB
3 times weekly for 
24 doses (8 weeks) 
3a INH 
RIF 
3 times weekly for 54 
doses (18 weeks) ¶ 
78 
(26 weeks) 
4 INH 
RIF 
EMB 
7 days/week for 56 doses  
(8 weeks) 
or
5 days/week for 40 doses 
(8 weeks) ¶ 
4a INH 
RIF 
7 days/week for 217
doses (31 weeks) 
or
5 days/week for 155
doses (31 weeks) ¶ 
273-195 
(39 weeks) 
4b# INH 
RIF 
Twice weekly for 62 
doses (31 weeks) ¶ 
(118-102) 
(39 weeks) 
INH = isoniazid   RIF = rifampin PZA = pyrazinamide   EMB = ethambutol   RPT = rifapentine 
*For more information on strength of recommendation and quality of supporting evidence, refer to ATS, CDC, and 
IDSA MMWR Treatment of Tuberculosis Guidelines. 
± When DOT is used, drugs may be given 5 days/week and the necessary doses adjusted accordingly. 
§ Patients with cavitation on initial chest x-ray and positive cultures at completion of 2 months of therapy should 
receive a 7-month continuation phase. 
¶ Patients on regimens given less than 7 days a week should receive DOT 
# Regimens give less than 3 times a week are not recommended for HIV-infected patients with CD4+ counts less 
than a 100
**Used only for HIV-negative patients with negative sputum smears at completion of 2 months of therapy and who
do not have cavitation on initial chest x-ray. For patients started on this regimen and found to have positive culture 
from the 2-month specimen, treatment should be extended an extra 3 months.  
26
 
 
 
  
      
 
     
  
     
  
 
     
 
 
  
 
    
 
  
 
 
 
    
  
 
      
 
 
        
Treatment of Latent Tuberculosis Infection and Tuberculosis Disease 
Table 4.4 

Dosage Recommendations for the Treatment of TB in Adults and Children1
 
Dose in mg/kg (maximum dosage in parentheses) 
Drug Adults/Children2 Daily 1 time/week3 2 times/week3 3 times/week3 
INH 
Adults 5 mg/kg (300 mg) 
15 mg/kg  
(900 mg) 
15 mg/kg  
(900 mg) 
15 mg/kg 
(900 mg) 
Children 10-15 mg/kg(300 mg) 
20-30 mg/kg
(900 mg) 
RIF 
Adults 10 mg/kg (600 mg) 
10 mg/kg 
(600 mg) 
10 mg/kg 
(600 mg) 
Children 10-20 mg/kg(600 mg) 
10-20 mg/kg
(600 mg) 
RBT 
Adults 5 mg/kg (300 mg) 
5 mg/kg 
(300 mg) 
5 mg/kg 
(300 mg) 
Children Appropriate dosing for children unknown 
RPT 
Adults
10 mg/kg  
(600 mg)
(continuation phase) 
Children This drug is not approved for use in children 
PZA 
Adults 
w
ei
gh
t 
40-55 kg 18.2-25 mg/kg (1000 mg) 
36.4-50 mg/kg 
(2000 mg) 
27.3-37.5 mg/kg 
(1500 mg) 
56-75 kg 20-26.8 mg/kg (1500 mg) 
40-53.6 mg/kg 
(3000 mg) 
33.3-44.6 
(2500 mg) 
76-90 kg 22.2-26.3 mg/kg (2000 mg) 
44.4-52.6 mg/kg 
(4000 mg) 
33.3-39.5 mg/kg 
(3000 mg) 
Children 15-30 mg/kg(2000 mg) 
50 mg/kg 
(2000 kg) 
EMB4 
Adults
w
ei
gh
t 
40-55 kg 14.5-20 mg/kg (800 mg) 
36.4-50 mg/kg 
(2000 mg) 
21.8-30 mg/kg 
(1200 mg) 
56-75 kg 16-21.4 mg/kg (1200 mg) 
37.3-50 mg/kg 
(2800 mg) 
26.7-35.7 mg/kg 
(2000 mg) 
76-90 kg 17.8-21.1 mg/kg (1600 mg) 
44.4-52.6 mg/kg 
(4000 mg) 
26.7-31.6 mg/kg 
(2400 mg) 
Children 15-20 mg/kg(1000 mg) 
50 mg/kg 
(2500 mg) 
INH= isoniazid  RIF= rifampin  RBT= rifabutin RPT= rifapentine  PZA= pyrazinamide EMB= ethambutol 
1Although these regimens are broadly applicable, modifications may be needed for certain circumstances (patients 

on ARVs). For more information, refer to the ATS, CDC, and IDSA MMWR Treatment of Tuberculosis Guidelines 

2 For purposes of this document adults dosing begins at age 15 years. Children weighing more than 40 kg should
 
be dosed as adults. Adjust doses as the patient’s weight changes. 

3All patients prescribed an intermittent regimen should be given DOT. 

4Ethambutol should be used with caution in young children since it is difficult to monitor their vision. However, 

if they have TB that is resistant to INH or RIF, dose of 15 mg/kg per day can be used. 
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reatment of Latent Tuberculosis Infection and Tuberculosis Disease 
Study Questions 4.14 – 4.17 
4.14 Why must TB disease be treated for at least 6 months?
4.15 Which four drugs are recommended for the initial treatment of TB disease?
4.16 Why should at least two drugs be used to treat TB disease? 
4.17 Name two factors that can lead to drug resistance. 
Answers to study questions are on pages 52 – 58. 
28
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment of Latent Tuberculosis Infection and Tuberculosis Disease 
. . . . . . . . . . . . . . . . . . . . . . . . 
HIV-infected TB patients 
should be closely monitored 
for their response to 
treatment. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
Treatment for pregnant 
women who have TB disease 
should begin as soon as TB is 
diagnosed. 
. . . . . . . . . . . . . . . . . . . . . . . . 
Special Considerations 
People Living with HIV  
The management of HIV-infected TB patients can be 
complex and therefore medical experts should be involved 
in the care and treatment of the patients. The treatment 
regimens listed in Table 4.3 are also effective for people 
living with HIV with two exceptions:
	 Once weekly administration of isoniazid and 
rifapentine in the continuation phase should not be 
used in any HIV-infected patient. 
	 Patients with advanced HIV (CD4 counts less than 
100) should be treated with daily or three times 
weekly therapy in both the initial and continuation 
phase
HIV-infected TB patients should receive a minimum of at 
least 6 months of treatment and be closely monitored for 
their response to treatment. If they do not seem to be 
responding to treatment, they should be reevaluated and the 
continuation phase can be increased to 7 months (a total of 
9 months of treatment) if necessary. 
DOT should be used in all HIV-infected TB patients. If the 
HIV-infected TB patient is on ARVs, it is important to be 
aware of the interaction of rifampin with some ARV drugs. 
Rifabutin has fewer drug interaction problems and may be 
used as a substitute for rifampin.  
Pregnant Women 
Treatment should not be delayed for pregnant women who 
have TB disease; rather, it should begin as soon as TB is 
diagnosed. The preferred initial regimen for pregnant 
women who have TB is isoniazid, rifampin, and 
ethambutol for at least 9 months. In most cases, 
pyrazinamide should NOT be used because there is not 
enough information about how this drug affects the fetus. 
Streptomycin, a second-line TB drug, should NOT be used 
because it has been shown to have harmful effects on the 
fetus. Vitamin B6 supplements are recommended for all 
pregnant women who are taking isoniazid.
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atment of Latent Tuberculosis Infection and Tuberculosis Disease 
. . . . . . . . . . . . . . . . . . . . . . . . 
The treatment of TB is 
essentially the same for 
children and adults. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
Infants and children with 
miliary TB, bone and joint 
TB, or TB meningitis should 
receive 9-12 months  
of treatment. 
. . . . . . . . . . . . . . . . . . . . . . . . 
Breastfeeding 
Women being treated with the first-line TB drugs should 
not be discouraged from breastfeeding. Only a small 
concentration of the drugs is found in the breast milk and it 
is not harmful to the infant. The concentration of drugs 
found in breast milk should not be considered to be 
effective treatment for LTBI or TB disease for the nursing 
infant. Vitamin B6 supplements are recommended for all 
women who are taking isoniazid and are breastfeeding.
Children and Adolescents 
TB treatment in infants and children younger than 4 years 
of age should be started as soon as the diagnosis is 
suspected. It is recommended that children be treated for 6 
months. Children commonly develop primary TB. 
Primary TB generally affects the mid and lower lung. 
Children should be treated with 3 (rather than 4) drugs in 
the initial phase (isoniazid, rifampin, and pyrazinamide). 
Ethambutol is generally not recommended for children, 
unless there is an increased chance of either isoniazid-
resistance TB or TB that is consistent with reactivation 
TB (see New Terms, p.3). Pills given to children may have 
to be crushed or given in a liquid form. It is not 
recommended to treat children three times a week. 
People with Extrapulmonary TB 
In general, regimens that are used for treating pulmonary 
TB are also effective for treating extrapulmonary TB. 
However, infants and children with miliary TB, bone and 
joint TB, or TB meningitis should receive at least 9-12 
months of treatment. 
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Treatment of Latent Tuberculosis Infection and Tuberculosis Disease 
. . . . . . . . . . . . . . . . . . . . . . . . 
The treatment of drug-
resistant TB should always be 
done under the supervision of 
a medical expert who is 
familiar with the treatment  
of drug-resistant TB. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
When TB is resistant to 
isoniazid and rifampin, 
treatment can last 2 years  
or longer. 
. . . . . . . . . . . . . . . . . . . . . . . . 
Alternative Regimens 
Alternative regimens should be used for treating drug-
resistant TB. The treatment of drug-resistant TB should 
always be done under the supervision of a medical expert 
who is familiar with the treatment of drug-resistant TB. 
People with Isoniazid-Resistant TB
Isoniazid-resistant TB can be treated with the 
recommended 6-month, three-drug regimen (rifampin, 
ethambutol, and pyrazinamide). It can also be treated with 
rifampin and ethambutol for 12 months. 
People with TB Resistant to Isoniazid and Rifampin  
(MDR TB)
It is more difficult to treat MDR TB than it is to treat drug-
susceptible TB. More drugs are required to treat MDR TB, 
and these drugs are less effective and more likely to cause 
adverse reactions. When TB is resistant to isoniazid and 
rifampin, treatment can last 2 years or longer. As a last 
resort, some patients with MDR TB undergo surgery to 
remove part of the infected site. 
People with Extensively Drug-Resistant TB  
(XDR TB)
Extensively drug resistant TB (XDR TB) is a rare type of 
MDR TB. XDR TB is defined as TB which is resistant to 
isoniazid and rifampin, plus resistant to any 
fluoroquinolone and at least one of three injectable second-
line drugs (i.e., amikacin, kanamycin, or capreomycin). 
Because XDR TB is resistant to first-line and second-line 
drugs, patients are left with less effective treatment options. 
XDR TB is difficult to treat and successful outcomes for 
the patient depend greatly on the extent of drug resistance, 
the severity of the disease, and whether the patient’s 
immune system is compromised.  
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tment of Latent Tuberculosis Infection and Tuberculosis Disease 
Study Questions 4.18 – 4.19 
4.18	 What treatment regimens should be used for HIV-infected TB patients? 
4.19	 In what special situations should treatment for TB disease last longer than the 
usual course of treatment?
Answers to study questions are on pages 52 – 58. 
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Treatment of Latent Tuberculosis Infection and Tuberculosis Disease 
Case Study 4.3 
An 18-month-old girl is admitted to the hospital because of meningitis. Doctors 
discover that her grandmother had pulmonary TB and was treated with a 6­
month regimen. The medical evaluation of the child confirms the diagnosis of TB 
meningitis. 
 For how long the child should be treated? 
Answers to case study questions are on pages 59 – 62. 
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eatment of Latent Tuberculosis Infection and Tuberculosis Disease 
. . . . . . . . . . . . . . . . . . . . . . . . 
Each TB patient should have 
a specific treatment and 
monitoring plan developed in 
collaboration with the local 
health department. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
Before starting treatment, 
adult patients should have 
baseline tests to help detect 
any abnormalities that may 
complicate treatment. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
All patients being treated for 
TB disease should be 
educated about the symptoms 
caused by adverse reactions 
to the drugs they are taking. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
All patients should be seen 
by a clinician at least 
monthly during treatment and 
evaluated for possible 
adverse reactions. 
. . . . . . . . . . . . . . . . . . . . . . . . 
Treatment and Monitoring Plan 
For each patient with newly diagnosed TB, a specific 
treatment and monitoring plan should be developed in 
collaboration with the local health department. This should 
be done within one week of the suspected diagnosis. This 
plan should include 
	 a description of the treatment regimen 
	 methods of monitoring for adverse reactions 
	 methods of assessing and ensuring adherence to the 
treatment  
	 methods for evaluating treatment response  
For detailed information on treating TB, refer to the ATS, 
CDC, and IDSA Treatment of Tuberculosis guidelines. 
Monitoring for Adverse Reactions
Before starting treatment, adult patients should have certain 
baseline blood and vision tests to help detect any problems 
that may complicate treatment. For children, only vision 
tests are necessary unless there are other medical 
conditions that may complicate treatment. Follow-up tests 
should be done periodically if the results of the baseline 
tests indicate abnormalities or if the patient has symptoms 
that may be due to adverse reactions. 
As with patients receiving LTBI treatment, all patients 
being treated for TB disease should be educated about the 
symptoms that are caused by adverse reactions to the 
drugs they are taking (Table 4.5). The patients should be 
warned about the symptoms of insignificant (minor) side 
effects, such as the orange discoloration of the urine from
rifampin, as well as the symptoms of potentially serious 
side effects, such as vomiting or abdominal pain. Patients 
should be instructed to seek medical attention immediately 
if they have symptoms of a serious side effect. 
All patients should be seen by a clinician at least monthly 
during treatment and evaluated for possible adverse 
reactions. Monitoring for adverse reactions must be 
individualized, depending on the drugs the patient is taking 
and the patient’s risk for adverse reactions.  
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During this evaluation, clinicians should ask patients 
whether they have any of the symptoms that may be due to 
adverse reactions and examine patients for signs of 
possible adverse reactions. 
Also, public health workers who have regular contact with 
patients should ask patients about adverse reactions at 
every visit. If a patient has symptoms of a serious adverse 
reaction, the public health worker should
	 Instruct the patient to stop the medication if the 
symptoms are serious (before working with TB 
patients, public health workers should be educated 
about which symptoms are serious) 
	 Report the situation to a clinician and arrange for a 
medical evaluation right away 
	 Note the symptoms on the patient’s form
35 

  
 
T
 36
 
  
 
  
 
  
 
 
 
 
 
 
 
reatment of Latent Tuberculosis Infection and Tuberculosis Disease 
Table 4.5 

Common Adverse Reactions to TB Drugs 

Caused by Adverse Reaction Signs and Symptoms Significance 
of Reaction* 
Any drug Allergic  Skin rash Serious 
Ethambutol Eye damage Blurred or changed vision 
Changed color vision 
Serious 
Isoniazid 
Pyrazinamide 
Rifampin
Hepatitis Abdominal pain 
Abnormal liver function test results 
Dark urine 
Fatigue 
Fever for 3 or more days 
Flulike symptoms 
Lack of appetite 
Nausea 
Vomiting 
Yellowish skin or eyes 
Serious 
Isoniazid Nervous system
damage 
Dizziness 
Tingling or numbness around the 
mouth 
Serious 
Peripheral 
neuropathy 
Tingling sensation in hands and feet Serious 
Pyrazinamide Stomach upset Stomach upset, vomiting, lack of
appetite 
Serious 
Increased uric acid Abnormal uric acid level 
Joint aches
Gout (rare) 
Serious 
Rifampin Bleeding problems Easy bruising 
Slow blood clotting 
Serious 
Discoloration of 
body fluids 
Orange urine, sweat, or tears 
Permanently stained soft contact 
lenses 
Minor 
Drug interactions Interferes with certain medications, 
such as birth control pills, birth 
control implants, and methadone 
treatment 
May be 
Serious or 
Minor 
Sensitivity to the 
sun 
Frequent sunburn Minor 
*Patients should stop medication for serious adverse reactions and consult a clinician immediately.
Patients can continue taking medication if they have minor adverse reactions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Treatment of Latent Tuberculosis Infection and Tuberculosis Disease 
Study Questions 4.20 – 4.22 
4.20	 What should be included in each patient’s treatment plan?  
4.21	 Name the drug or drugs that may cause each of the following symptoms or 
adverse reactions. 
Nervous system damage: 
Hepatitis: 
Eye damage: 

Orange discoloration of the urine: 

4.22	 How often should patients be monitored for adverse reactions to TB drugs?
Answers to study questions are on pages 52 – 58. 
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Case Study 4.4 
You are assigned to deliver medications to TB patients as part of the directly 
observed therapy program where you work. When you visit Mr. Jackson’s house, 
you ask him how he is feeling. He tells you that he was up all night vomiting.  
 What are the possible causes? 
Answers to case study questions are on pages 59 – 62. 
Case Study 4.5 
Ms. Young, a patient who started treatment for TB disease last week, calls the TB 
clinic to complain that her urine has changed to a funny color.  
 Name two possible causes, and explain how each would affect the color 
of the urine. 
Answers to case study questions are on pages 59 – 62. 
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. . . . . . . . . . . . . . . . . . . . . . . . 
In order to cure TB and 
prevent drug resistance, 
patients with TB must  
adhere to treatment. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
Directly observed therapy 
should be considered for all 
patients because there is no 
way to predict reliably 
which patients will adhere  
to treatment. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
Another way to improve 
patient adherence is to offer 
incentives or enablers. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
An important part of helping 
patients take their medicine is 
to educate them about TB.  
. . . . . . . . . . . . . . . . . . . . . . . . 
Adherence to Treatment 
Treatment for TB disease lasts longer and requires more 
drugs than treatment for other infectious diseases. In order 
to cure TB and prevent drug resistance, patients with TB 
must follow the recommended course of treatment. This is 
called adhering to treatment. However, ensuring that 
patients adhere to treatment can be difficult because many 
patients are reluctant to take several different medications 
for many months. 
There are many ways to encourage patients to adhere to 
treatment. The most effective strategy is directly observed 
therapy (DOT). DOT means that a health care worker or 
another designated person watches the TB patient swallow 
each dose of the prescribed drugs. This method of 
treatment should be considered for all patients because 
there is no way to predict reliably which patients will 
adhere to treatment. DOT should be done at a time and a 
place that are convenient for the patient. For example, 
health care workers can meet TB patients at work, at home, 
or in other locations to provide DOT. 
DOT should be used for all children and adolescents. Even 
when drugs are given under DOT, tolerance of the 
medication must be monitored closely. Parents should not 
be relied on to supervise DOT. 
Another way to improve patient adherence is to offer 
incentives or enablers. Incentives are small rewards given 
to patients to encourage them to take their own medicines 
or to keep their DOT or clinic appointments. For example, 
patients may be given food, restaurant coupons, clothing, 
or other items as an incentive. Enablers are things that help 
the patient receive treatment, such as bus tokens to get to 
the clinic. Incentives and enablers should be chosen 
according to the patient’s needs, and they are frequently 
offered along with DOT. 
An important part of helping patients take their medicine is 
to educate them about TB. This means talking to them
about the cause of TB, the way TB is spread, the methods 
of diagnosing TB, and the specific treatment plan. 
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. . . . . . . . . . . . . . . . . . . . . . . . 
In order to cure TB and 
prevent drug resistance, 
patients with TB must  
adhere to treatment. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
Patients who are not 
receiving directly observed 
therapy should be monitored 
carefully for adherence to 
treatment. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
The best way to ensure 
adherence to treatment is to 
use directly observed therapy. 
. . . . . . . . . . . . . . . . . . . . . . . . 
Health care providers should take the time to clearly 
explain to patients when the medication should be taken, 
how much, and how often, especially if the patient is not 
receiving DOT. Written instructions should also be 
provided. Patients who understand these concepts are more 
likely to adhere to treatment.  
In summary, in order to prevent relapse and drug 
resistance, clinicians must prescribe an adequate regimen 
and make sure that patients adhere to treatment.  
Monitoring Patients’ Adherence to Therapy
Patients who are not receiving directly observed therapy 
(self-administered therapy) should be monitored carefully 
for adherence to treatment. This can be done in at least four 
ways: 
	 Check to see whether the patient is reporting to the 
clinic as scheduled, and ask the patient about 
adherence 
	 Ask the patient to bring the prescribed medications to 
each clinic visit and count the number of pills to 
determine how many have been taken 
	 Use special urine tests to detect the presence of the 
prescribed medication in the urine 
	 Assess the patient’s clinical response to treatment
None of these methods can be used to prove that a patient 
is taking every dose of the prescribed medication. The best 
way to ensure adherence to treatment is to use directly 
observed therapy. For more information on patient 
adherence, please refer to Self Study Modules on 
Tuberculosis, 6-9. 
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. . . . . . . . . . . . . . . . . . . . . . . . 
Clinicians can evaluate a 
patient’s response to 
treatment by checking to
see whether the patient still 
has symptoms of TB. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
Patients whose symptoms do 
not improve during the first  
2 months of treatment, or 
whose symptoms worsen 
after improving initially,
should be reevaluated. 
. . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
Sputum specimens should be 
examined every month until 
the culture results have 
converted from positive to 
negative. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
Patients should have a chest 
x-ray at the end of treatment 
so that it can be compared 
with any chest x-rays given 
later on. 
. . . . . . . . . . . . . . . . . . . . . . . . 
Evaluating Patients’ Response to Treatment
Clinicians use three methods to determine whether a 
patient is responding to treatment. First, they can check to 
see whether the patient still has symptoms of TB (clinical 
evaluation). Although each patient responds to treatment at 
a different pace, all patients’ TB symptoms should 
gradually improve and eventually go away. Patients whose 
symptoms do not improve during the first 2 months of 
treatment, or whose symptoms worsen after improving 
initially, should be reevaluated. 
Public health workers who have regular contact with 
patients should pay attention to the patients’ improvement. 
If a patient has symptoms of TB (or of serious adverse 
reactions), they should report the situation to the clinician 
and arrange for a medical evaluation right away. They 
should also note the symptoms on the patient’s forms.  
Second, clinicians can check a patient’s response to 
treatment by doing a bacteriologic examination of the 
sputum or other specimens. Specimens should be examined 
at least every month until the culture results have converted 
from positive to negative. Any patient whose culture results 
have not become negative after 2 months of treatment, or 
whose culture results become positive after being negative, 
should be carefully reevaluated. 
Third, clinicians can use x-rays to monitor a patient’s 
response to treatment. Repeated x-rays are not as important 
as monthly bacteriologic and clinical evaluations. 
However, an x-ray taken at the end of treatment can be 
compared with any follow-up x-rays taken subsequently 
should symptoms recur. X-rays are also useful for patients 
who have negative culture results before treatment. In these 
patients, the bacteriological response may be difficult to 
assess, and the clinician may have to rely on the clinical 
and x-ray responses. 
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. . . . . . . . . . . . . . . . . . . . . . . . 
The TST or QFT-G cannot be 
used to determine whether a 
patient is responding to 
treatment. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
Any patient who has not 
responded to treatment after  
2 months or who has relapsed 
should be reevaluated 
promptly. 
. . . . . . . . . . . . . . . . . . . . . . . . 
The TST or QFT-G cannot be used to determine whether a 
patient is responding to treatment. This is because most 
people who have a positive TST result will have a positive 
result again if they are skin tested later in their lives, 
regardless of whether they have received treatment. 
Currently, there is not enough information on the use of 
QFT-G to determine treatment response (see Module 3, 
Targeted Testing and the Diagnosis of Latent Tuberculosis 
Infection and Tuberculosis Disease).
Treatment completion is defined by the number of doses 
that patient takes within a specific time frame. The length 
of therapy depends on the drugs used, the drug 
susceptibility test result and the patient’s response to 
therapy. 
Reevaluating Patients Who Do Not Respond to 
Treatment or Who Relapse 
Patients should be reevaluated promptly if their 
	 Symptoms do not improve during the first 2 months 
of therapy 
	 Symptoms worsen after improving initially 
	 Culture results have not become negative after 2 

months of treatment 

	 Culture results become positive after being negative 
Reevaluating the patient means checking for drug 
resistance by repeating the drug susceptibility tests and 
assessing whether the patient has been taking medication as 
prescribed.
The treatment of TB can be complicated, especially in 
patients who fail to respond to treatment, who relapse, or 
who have drug-resistant TB or serious adverse reactions to 
medications. A new regimen may be required, and 
treatment may last longer. Clinicians who do not have 
experience with these situations should consult a medical 
expert. 
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Treatment of Latent Tuberculosis Infection and Tuberculosis Disease 
Study Questions 4.23 – 4.27 
4.23 Name four ways by which clinicians can assess whether a patient is adhering to 
treatment. 
4.24 What is the best way to ensure that a patient adheres to treatment? 
4.25 How can clinicians determine whether a patient is responding to treatment?
4.26 Under what circumstances should patients be reevaluated?
4.27 What does reevaluating the patient mean? 
Answers to study questions are on pages 52 – 58. 
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Case Study 4.6 
Mr. Vigo was diagnosed with smear-positive pulmonary TB in January. He was 
treated with isoniazid, rifampin, and pyrazinamide by his private physician. He 
visited his physician again in March. His drug susceptibility test results were not 
available at the time of this appointment. Nevertheless, the physician discontinued
his prescription of pyrazinamide and gave him refills of isoniazid and rifampin. 
Mr. Vigo visited his physician again in April. He had a persistent cough, and his 
sputum smear was found to be positive. 
 What should be done next? 
Answers to case study questions are on pages 59 – 62.  
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. . . . . . . . . . . . . . . . . . . . . . . . 
Case management is a 
strategy that can be used to 
ensure that patients complete 
TB treatment. 
. . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . 
At each visit with a TB 
patient, public health workers 
should look for signs and 
symptoms of adverse 
reactions to the medication. 
. . . . . . . . . . . . . . . . . . . . . . . . 
What Is the Role of the Public Health Worker 
in TB Treatment? 
Successful TB treatment is the responsibility of the medical 
providers and health care workers, not the patient. Public 
health workers in TB programs and other facilities play an 
important role in helping patients complete LTBI or TB 
treatment.  
A strategy that may be used to ensure patients complete TB 
treatment is case management. There are three elements of 
case management: 
	 Assignment of a health department employee to 

manage specific patients   

	 Systematic regular review of each patient’s treatment 
progress 
	 Plans to address barriers to adherence 
In case management, a health department employee is 
assigned responsibility for the management of specific 
patients. This person is held accountable for ensuring that 
each of their patients is educated about TB treatment and 
that their therapy is continuous. 
Many public health workers provide directly observed 
therapy (DOT) or have regular contact with TB patients in 
clinics, nursing homes, drug treatment centers, or other 
facilities. At each visit with a patient, public health workers 
should look for signs and symptoms of adverse reactions
to the medication. For this reason, public health workers 
must be familiar with the signs and symptoms of serious 
and minor adverse reactions to the drugs commonly used to 
treat TB. If a patient has symptoms of an adverse reaction, 
the public health worker should 
	 Instruct the patient to stop the medication if the 
symptoms are serious (Before working with TB 
patients, public health workers should be educated 
about which symptoms are serious) 
	 Report the situation to a clinician and arrange for a 
medical evaluation right away 
	 Note the symptoms on the patient’s form
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. . . . . . . . . . . . . . . . . . . . . . . . 
Public health workers can 
help monitor a patient’s 
response to treatment for  
TB disease by looking for 
symptoms of TB disease. 
. . . . . . . . . . . . . . . . . . . . . . . . 
Also, public health workers can help monitor a patient’s 
response to treatment for TB disease by looking for 
symptoms of TB disease. Patients receiving treatment for 
TB disease usually have symptoms at the beginning of 
therapy, such as coughing, fatigue, and fever. These 
symptoms should gradually improve and eventually go 
away. At each visit with a patient, public health workers 
should pay attention to the patient’s improvement.  
In addition to providing DOT, public health workers may 
be responsible for locating patients who have missed DOT 
visits or clinic appointments and helping them return to 
treatment. They may also educate patients and their 
families about TB, serve as interpreters, arrange and 
provide transportation for patients, and refer patients to 
other social services as needed. Finally, in many areas 
public health workers work with physicians in private 
practice (physicians who do not work in the health 
department) to make sure that their TB patients complete 
an adequate regimen for TB treatment. For more 
information on case management, please refer to Self Study 
Modules on Tuberculosis, 6-9. 
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Treatment of Latent Tuberculosis Infection and Tuberculosis Disease 
Study Question 4.28- 4.29 
4.28	 What are the three elements of case management? 
4.29	 What should a public health worker do if he or she notices that a patient has 
symptoms of an adverse reaction?
Answers to study questions are on pages 52 – 58. 
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Case Study 4.7 
Ms. DeVonne began treatment for pulmonary TB disease 2 months ago, at the 
beginning of September. You have been giving her directly observed therapy. 
During the first few weeks of therapy, you noticed that Ms. DeVonne’s symptoms
were improving a little. However, at a visit in October, you see that Ms. DeVonne 
is coughing up blood, and she tells you that she feels like she has a fever. 
 What should you do? 
Answers to case study questions are on pages 59 – 62. 
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SUMMARY 
LTBI treatment is medication that is given to people who have TB infection to prevent them
from developing TB disease. Some people with LTBI are at higher risk of developing TB 
disease, and they should be evaluated and receive higher priority for LTBI treatment if they have 
a positive TST or QFT-G result. All patients being considered for LTBI treatment should receive 
a medical evaluation to  
 Exclude the possibility of TB disease 
 Determine whether they have ever been treated for TB infection or disease 
 Identify any medical problems that may complicate therapy or require more careful 
monitoring 
 Determine if patient is taking a medication which may interact with LTBI treatment drugs 
Generally, people who have already completed treatment for LTBI or TB disease do not need to 
be retreated again for LTBI. 
The usual regimen for LTBI treatment is isoniazid given daily for 9 months for both adults and 
children. Sometimes LTBI treatment is given to people who have a negative TST or QFT-G 
result, such as high-risk contacts and children younger than 6 months old who have been exposed 
to TB. 
Patients should be evaluated every month for signs of hepatitis and other adverse reactions to 
isoniazid. They should also be educated about the symptoms caused by serious adverse reactions 
to isoniazid and instructed to seek medical attention immediately if these symptoms occur. In 
addition, people at greatest risk for hepatitis should have liver function tests before starting LTBI 
treatment and during therapy.  
Patients should be given documentation of LTBI treatment upon completion. 
TB disease must be treated for at least 6 months; in some cases, treatment lasts even longer. The 
initial regimen for treating TB disease should include four drugs: isoniazid, rifampin, 
pyrazinamide, and ethambutol. When the drug susceptibility results are available, clinicians may 
change the regimen accordingly. The TB treatment regimen must include at least two drugs to 
which the bacilli are susceptible. Using only one drug to treat TB disease can create a population 
of tubercle bacilli that is resistant to that drug. Drug resistance can also develop when patients do 
not take treatment as prescribed. Thus, to prevent relapse and drug resistance, clinicians must 
prescribe an adequate regimen and make sure that patients adhere to treatment. The best way to 
ensure that patients adhere to treatment is to use directly observed therapy.  
There are several options for daily and intermittent therapy. Treatment may last longer or involve 
different regimens for children with certain types of extrapulmonary TB, pregnant women, 
people living with HIV, or people with drug-resistant TB. For people living with HIV and people 
with drug-resistant TB, treatment should be provided under the supervision of a medical expert 
who is familiar with the treatment. 
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All patients being treated for TB disease should be educated about the symptoms caused by 
adverse reactions to the drugs they are taking and instructed to seek medical attention
immediately if they have symptoms of a serious side effect. Patients should be seen by a 
clinician at least monthly during treatment and evaluated for possible adverse reactions. In 
addition, before starting treatment, patients should have baseline tests to help clinicians detect 
any abnormalities that may complicate treatment.  
Patients who are not receiving directly observed therapy should be carefully monitored for 
adherence to treatment. However, the only way to ensure adherence to treatment is to use 
directly observed therapy. 
To determine whether a patient is responding to treatment, clinicians should do clinical 
evaluations and bacteriologic evaluations during treatment. Patients should be carefully 
reevaluated if their 
 Symptoms do not improve during the first 2 months of treatment 
 Symptoms worsen after improving initially 
 Culture results have not become negative after 2 months of treatment 
 Culture results become positive after being negative 
In certain situations, clinicians may also use chest x-rays to monitor a patient’s response to 
treatment. 
The treatment of TB can be complicated, especially in patients who fail to respond to treatment, 
who relapse, or who have drug-resistant TB or adverse reactions to medications. Clinicians who 
do not have experience with these situations should consult a medical expert. 
Successful TB treatment is the responsibility of the medical providers and the health care 
workers, not the patient. Case management is a strategy that can be used to ensure patients 
complete TB treatment. At each visit with a patient, public health workers should look for signs 
and symptoms of adverse reactions to the medication. If a patient has symptoms of a serious 
adverse reaction, the public health worker should  
 Instruct the patient to stop the medication if the symptoms are serious  
 Report the situation to a clinician and arrange for a medical evaluation right away 
 Note the symptoms on the patient’s form
Also, public health workers should pay attention to the patient’s improvement. If a patient has 
symptoms of TB, public health workers should  
 Report the situation to a clinician and arrange for a medical evaluation right away 
 Note the symptoms on the patient’s form
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Treatment of Latent Tuberculosis Infection and Tuberculosis Disease 
ANSWERS TO STUDY QUESTIONS 
4.1	 What is the purpose of LTBI treatment? (page 4)
The purpose of LTBI treatment is to prevent people with latent TB infection from
developing TB disease. 
4.2	 Which groups of people should receive high priority for LTBI treatment if they have 
a positive QFT-G result or TST reaction with an induration that is 5 millimeters or 
larger? Name four.  (page 5)
	 People with HIV infection 
	 Recent close contacts of people with infectious TB disease 
	 People with chest x-ray findings suggestive of previous TB disease  
	 Patients with organ transplants 
	 Other immunosuppressed patients (such as patients on prolonged therapy with 
corticosteroids, equivalent to taking 15 mg or more of prednisone for at least 1 
month, or those taking TNF-alpha antagonists) 
4.3	 Which groups of people should receive high priority for LTBI treatment if they have 
a positive QFT-G result or TST reaction with an induration that is 10 millimeters or 
larger? Name seven. (page 5)
	 People who have come to the U.S. within the last 5 years from areas of the world 
where TB is common (for example, Asia, Africa, Eastern Europe, Russia, or Latin 
America) 
	 People who inject illegal drugs 
	 People who live or work in high-risk facilities (for example, nursing homes, 
correctional facilities, homeless shelters, hospitals, or other health care facilities) 
	 People who work in mycobacteriology laboratories 
	 People with medical conditions that appear to increase the risk for TB disease 
(silicosis, diabetes mellitus, severe kidney disease, certain types of cancer, and 
certain intestinal conditions) 
	 Children younger than 4 years old 
	 Infants, children, and adolescents exposed to adults in high-priority groups 
4.4	 What is the preferred LTBI treatment regimen? (page 8)
The preferred regimen for LTBI treatment is isoniazid given daily for 9 months. Nine 
months of isoniazid for LTBI treatment is very effective in preventing the development of 
TB disease in both people infected with HIV and those not infected with HIV.   
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4.5	 What LTBI treatment regimen may be recommended for people with a positive TST 
or QFT-G result who have been exposed to isoniazid-resistant TB?  (page 8)
Treatment with rifampin for 4 months may be recommended in this situation. 
4.6	 In what circumstances may LTBI treatment be given to people who have a negative 
TST or QFT-G result? (pages 11-12)
Some close contacts may start taking LTBI treatment if they have a negative skin test but 
less than 8 to 10 weeks have passed since they were last exposed to TB. These contacts 
include 
	 Children who are 5 years old or younger (some TB programs may have different age 
cutoff guidelines) 
	 People living with HIV 
	 Other immunosuppressed persons who may develop TB disease quickly after 
infection 
Because less than 8 to 10 weeks have passed since they were last exposed to TB, these 
contacts may be infected with M. tuberculosis but have a false-negative TST reaction (see 
Module 3, Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and 
Tuberculosis Disease). Once active TB disease is ruled out, they should start LTBI 
treatment to prevent them from rapidly developing TB disease. These contacts should be 
retested 8 to 10 weeks after they were last exposed to TB. If they have a negative TST or 
QFT-G, they can stop taking the LTBI treatment. If they have a positive TST or QFT-G 
result, they should continue to take LTBI treatment. HIV-infected contacts or others with a 
weakened immune system may be given a full course of LTBI treatment regardless of their 
TST or QFT-G result. 
4.7	 What conditions must be met to stop LTBI treatment for children, 5 years and 
younger, who were exposed to TB? (page 13)
Children 5 years and younger who have been exposed to TB should start taking the LTBI 
treatment, even if they have a negative skin test or QFT result. The children should be 
retested 8 to 10 weeks after they were last exposed to TB. The LTBI treatment can be 
stopped if all of the following conditions are met: 
	 The second skin test is negative. 
	 The second skin test was done 8 to 10 weeks after the child was last exposed to TB. 
	 The child is at least 6 months old. 
4.8	 When should pregnant women be treated for LTBI and for how long? (page 14)
For most pregnant women with TB infection, LTBI treatment can be delayed until after 
delivery. If the pregnant woman is HIV-infected or a recent contact immediate treatment 
should be considered. The preferred LTBI treatment regimen for pregnant women is 9 
months of isoniazid with a vitamin B6 supplement. 
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4.9	 Name four reasons why patients should receive a medical evaluation before starting 
LTBI treatment. (page 17-18)
All patients being considered for LTBI treatment should receive a medical evaluation to  
 Exclude the possibility of TB disease 
	 Determine whether they have ever been treated for TB infection or disease 
	 Identify any medical problems that may complicate therapy or require more careful 
monitoring
	 Establish and build rapport with patient
4.10 Why is it important to exclude the possibility of TB disease before giving a patient 
LTBI treatment? (page 17)
 
It is important to exclude the possibility of TB disease because treating TB disease with a 

LTBI treatment regimen (usually a single drug) can lead to drug resistance. 

4.11 What are the symptoms of hepatitis? (page 18)
The common symptoms of hepatitis are nausea, vomiting, abdominal pain, fatigue, and 
dark urine. 
4.12 Who is at greatest risk for hepatitis? What special precautions should be taken for 
these patients? (page 20)
The people at greatest risk for hepatitis are 

 People living with HIV 

	 People with a history of liver disorder or disease 
	 People who use alcohol regularly 
	 Women who are pregnant or just had a baby (within the last 3 months) 
	 People who are taking other medications that may increase the risk of hepatitis 
These patients should have liver function tests before starting isoniazid LTBI treatment, 
and during therapy. 
4.13 How often should patients be evaluated for signs and symptoms of adverse reactions 
during LTBI treatment?  (page 20)
All persons receiving LTBI treatment should be evaluated at least monthly during therapy 
for signs and symptoms of adverse reactions. During each monthly evaluation, clinicians 
should ask patients whether they have nausea, abdominal pain, or any of the other 
symptoms that may be caused by adverse reactions. In addition, they should examine 
patients for signs of these adverse reactions. 
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4.14 Why must TB disease be treated for at least 6 months?  	(page 23)
TB disease must be treated for at least 6 months; in some cases, treatment lasts even
longer. Most of the tubercle bacilli are killed during the first 8 weeks of treatment (the 
initial phase). However, a few bacilli can survive. Therefore, treatment must be continued 
for several more months to kill these remaining bacilli (the continuation phase). If 
treatment is not continued for a long enough time, the surviving bacilli may cause TB
disease in the patient at a later time (relapse). 
4.15 Which four drugs are recommended for the initial treatment of TB disease?   
(page 23)
The initial regimen for treating TB disease should include isoniazid (INH), rifampin (RIF), 
pyrazinamide (PZA), and ethambutol (EMB). When the drug susceptibility results are 
available, clinicians may change the regimen accordingly.  
4.16 Why should at least two drugs be used to treat TB disease?  	(page 24)
Using only one drug to treat TB disease can create a population of tubercle bacilli that is 
resistant to that drug. When two or more drugs are used together, each drug helps prevent 
the emergence of bacilli that are resistant to the other drugs.  
4.17 Name two factors that can lead to drug resistance.  (page 24)
Drug resistance can develop when patients are prescribed an inappropriate regimen for 
treatment or when patients do not follow treatment regimens as prescribed. 
4.18 What treatment regimens should be used for HIV-infected TB patients?  	(page 29)
The treatment regimens for HIV-infected TB patients are generally the same as for TB 
patients without HIV-infection with two exceptions:
	 Once weekly administration of isoniazid and rifapentine in the continuation phase 
should not be used in any HIV-infected patient. 
	 Patients with advanced HIV (CD4 counts less than 100) should be treated with daily 
or three times weekly therapy in both the initial and continuation phase
HIV-infected TB patients should receive a minimum of at least 6 months of treatment and 
be closely monitored for their response to treatment. If they do not seem to be responding 
to treatment, they should be reevaluated and the continuation phase can be increased to 7 
months (a total of 9 months of treatment) if necessary. 
DOT should be used in all HIV-infected TB patients. If the HIV-infected TB patient is on 
ARVs it is important to be aware of the interaction of rifampin with some ARV drugs. 
Rifabutin has fewer drug interaction problems and may be used as a substitute for rifampin.  
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4.19 In what special situations should treatment for TB disease last longer than the usual 
course of treatment? (pages 29-31)
 HIV-infected TB patients should receive a minimum of at least 6 months of 
treatment and be closely monitored for their response to treatment. If they do not 
seem to be responding to treatment, they should be reevaluated and the continuation 
phase can be increased to 7 months (a total of 9 months of treatment) if necessary. 
 Pregnant women with TB should receive at least 9 months of treatment, if PZA is 
not used. 
 Infants and children with miliary TB, bone and joint TB, or TB meningitis should 
receive at least 9-12 months of treatment. 
 Treatment for isoniazid-resistant TB can last 12 months when a regimen of rifampin 
and ethambutol is used; treatment for multidrug-resistant TB can last 2 years or 
longer. 
4.20 What should be included in each patient’s treatment plan? (page 34)
This plan should include 
 a description of the treatment regimen 
 methods of monitoring for adverse reactions 
 methods of assessing and ensuring adherence to the treatment  
4.21 Name the drug or drugs that may cause each of the following symptoms or adverse 
reactions. 	(page 36)
 Nervous system damage:  isoniazid 
 Hepatitis: isoniazid, pyrazinamide, rifampin 
 Eye damage:  ethambutol 
 Orange discoloration of the urine:  rifampin 
4.22 How often should patients be monitored for adverse reactions to TB drugs?   
(page 34)
All patients should be seen by a clinician at least monthly during treatment and evaluated 
for possible adverse reactions. During this evaluation, clinicians should ask patients 
whether they have any of the symptoms that may be due to adverse reactions and examine 
patients for signs of possible adverse reactions. Also, public health workers who have 
regular contact with patients should ask patients about adverse reactions at every visit.  
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4.23 Name four ways by which clinicians can assess whether a patient is adhering to 
treatment. (page 40)
 Check to see whether the patient is reporting to the clinic as scheduled 
 Ask the patient to bring the prescribed medications to each clinic visit and count the 
number of pills to determine how many have been taken 
 Use special urine tests to detect the presence of the prescribed medication in the 
urine 
 Assess the patient’s clinical response to therapy 
4.24 What is the best way to ensure that a patient adheres to treatment?  	(page 39)
The best way to ensure adherence to therapy is to use directly observed therapy. Directly 
observed therapy means that a health care worker or another designated person watches the 
patient swallow each dose of the prescribed drugs. This method of treatment should be 
considered for all patients, because there is no way to predict reliably which patients will 
adhere to treatment.  
4.25 How can clinicians determine whether a patient is responding to treatment?   
(pages 41)
To determine whether a patient is responding to therapy, clinicians should do clinical 
evaluations and bacteriologic evaluations during therapy. Clinicians may also use x-rays to 
monitor a patient’s response to treatment, especially in patients who have negative culture 
results before treatment or who have certain types of extrapulmonary TB.  
4.26 Under what circumstances should patients be reevaluated?  	(pages 42)
Patients should be reevaluated promptly if their 
 Symptoms do not improve during the first 2 months of therapy 
 Symptoms worsen after improving initially 
 Culture results have not become negative after 2 months of treatment 
 Culture results become positive after being negative 
4.27 What does reevaluating the patient mean?  	(page 42)
Reevaluating the patient means checking for drug resistance by repeating the drug 
susceptibility tests and assessing whether the patient has been taking medication as 
prescribed. 
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4.28 What are three elements of case management? (page 45)
A strategy that may be used to ensure patient’s complete TB treatment is case management. 
There are three elements of case management 
 Assignment of a health department employee to manage specific patients   
 Systematic regular review of each patient’s treatment progress  
 Plans to address barriers to adherence 
4.29 What should a public health worker do if he or she notices that a patient has 
symptoms of an adverse reaction?  (page 45)
The public health worker should 
	 Instruct the patient to stop the medication if the symptoms are serious (before 
working with TB patients, public health workers should be educated about which 
symptoms are serious)
	 Report the situation to a clinician and arrange for a medical evaluation right away 
	 Note the symptoms on the patient’s form
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ANSWERS TO CASE STUDIES 
4.1	 You are sent to visit the home of a TB patient who was admitted to the hospital last 
week and diagnosed with infectious TB disease. Living in the home are his wife and 
his 1-year-old daughter. Neither one has symptoms of TB disease. You give them both 
a tuberculin skin test and return 2 days later to read the results. You find that the 
wife has 14 mm of induration, but the daughter has no induration. 
 Should either one start LTBI treatment? 
Yes, both should start LTBI treatment. 
 Why or why not? 
The wife is a close contact of someone with infectious TB disease, and she has a 
positive skin test (5 mm for close contacts). Therefore, after receiving a medical 
evaluation (to rule out TB disease, determine whether she has ever been treated for 
TB infection or disease, and identify any medical problems that may complicate 
therapy), she should complete an entire course of LTBI treatment, regardless of her 
age. 
The daughter is also a close contact. Currently, she has a negative skin test. However, 
only 1 week has passed since she last spent time with her infectious father. It is 
possible that not enough time has passed for her to be able to react to the tuberculin 
skin test. In other words, her TST reaction may be a false-negative. At this point, it is 
impossible to determine whether she has TB infection. In addition, because she is a 
young child, she may develop TB disease very quickly after infection. 
For these reasons, the daughter should start LTBI treatment now and be retested 8-10 
weeks after she last spent time with her father. If she has a negative TST or QFT-G 
result on the repeat test, she may stop taking the medicine. If she has a positive TST 
or QFT-G result, she should complete an entire course of LTBI treatment (9 months 
for children). 
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4.2	 A 65-year-old man is prescribed isoniazid LTBI treatment because he is a close
contact of a person with infectious TB and he has an induration of 20 mm to the 
tuberculin skin test. His baseline liver function tests are normal, but he drinks a six­
pack of beer every day. 
	 What kind of monitoring is necessary for this patient while he is taking
isoniazid? 
Even though his liver function tests are normal, this man is at high risk of isoniazid-
associated hepatitis because he is older than 35 and abuses alcohol. He should be 
educated about the symptoms of adverse reactions to isoniazid and be instructed to 
seek medical attention immediately if these symptoms occur. Furthermore, once a 
month, he should be seen by a clinician. The clinician should ask him about his 
symptoms, examine him for signs of adverse reactions, and consider performing liver 
function tests. 
4.3	 An 18-month-old girl is admitted to the hospital because of meningitis. Doctors 
discover that her grandmother had pulmonary TB and was treated with a 6-month 
regimen. The medical evaluation of the child confirms the diagnosis of TB meningitis. 
	 How long should the child be treated? 
Infants and children with miliary TB, bone and joint TB, or TB meningitis should be 
treated for at least 12 months. 
4.4	 You are assigned to deliver medications to TB patients as part of the directly observed 
therapy program where you work. When you visit Mr. Jackson’s house, you ask him 
how he is feeling. He tells you that he was up all night vomiting.  
	 What are the possible causes? 
His vomiting may be a symptom of hepatitis (caused by isoniazid, rifampin, and 
pyrazinamide) or of stomach upset due to pyrazinamide. Mr. Jackson should be 
advised to stop his medication and the situation should be reported to the clinician 
immediately. Mr. Jackson should be given a medical evaluation right away. 
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4.5	 Ms. Young, a patient who started treatment for TB disease last week, calls the TB 
clinic to complain that her urine has changed to a funny color.  
	 Name two possible causes, and explain how each would affect the color of the 
urine. 
One possible cause is the discoloration of body fluids, a common side effect of 
rifampin. This would cause Ms. Young’s urine to turn orange. The clinic nurse, 
physician, or public health worker should explain to Ms. Young that orange urine and 
other body fluids is a side effect of rifampin and that this is NOT a serious condition. 
Another possible cause is hepatitis, which can be caused by isoniazid, rifampin, or 
pyrazinamide. Hepatitis, a serious condition, would cause Ms. Young’s urine to turn 
dark. If Ms. Young’s urine is dark, the situation should be reported to the clinician 
and Ms. Young should receive a medical examination right away. 
4.6	 Mr. Vigo was diagnosed with smear-positive pulmonary TB in January. He was 
treated with isoniazid, rifampin, and pyrazinamide by his private physician. He 
visited his physician again in March. His drug susceptibility test results were not 
available at the time of this appointment. Nevertheless, the physician discontinued his 
prescription of pyrazinamide and gave him refills of isoniazid and rifampin. Mr. Vigo 
visited his physician again in April. He had a persistent cough, and his sputum smear 
was found to be positive.  
	 What should be done next? 
Mr. Vigo’s persistent cough and positive sputum smear indicate that he is not 
responding to therapy. The most likely explanations are  
 That he is not taking his medications as prescribed, 
 That he has drug-resistant TB and the regimen he has been prescribed is not 
adequate to treat his TB, or 
 A combination of the two factors listed above. 
The initial drug susceptibility test results should be located, and susceptibility tests 
should be repeated on a recent sputum specimen. In addition, his adherence should be 
evaluated, and he should be given directly observed therapy if possible. 
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4.7	 Ms. DeVonne began treatment for pulmonary TB disease 2 months ago, at the 
beginning of September. You have been giving her directly observed therapy. During 
the first few weeks of therapy, you noticed that Ms. DeVonne’s symptoms were 
improving a little. However, at a visit in October, you see that Ms. DeVonne is 
coughing up blood, and she tells you that she feels like she has a fever. 
 What should you do? 
Coughing up blood and feeling feverish are symptoms of TB disease. You should 
report Ms. DeVonne’s symptoms to the clinician and arrange for her to receive a 
medical evaluation right away. Also, you should note Ms. DeVonne’s symptoms on 
her form. 
The fact that Ms. DeVonne’s TB symptoms got worse after improving initially 
indicates that she is not responding to therapy. Because she is receiving directly 
observed therapy, Ms. DeVonne is probably taking her medications as prescribed. 
Therefore, the most likely explanation is that she has drug-resistant TB and the 
prescribed regimen is not adequate to treat the TB. 
Ms. DeVonne’s initial drug susceptibility test results should be located, and drug 
susceptibility tests should be repeated on a recent sputum specimen. 
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